Kelix bio Ltd
Sector: Manufacturing (Industrial) • Location: Supraregional
Source: Deutsche Investitions- und Entwicklungsgesellschaft (DEG)
KELIX bio Ltd. (“Kelix bio”) was created in 2020 by the PE investor Development Partners International LLP (DPI), EBRD and BII (former CDC) to become the consolidating group holding of the African build-and buy-platform. The platform’s strategy is to build a vertically integrated manufacturer and wholesaler of specialty generics and biosimilar drugs in fast growing segments like oncology, diabetes
- Status
- Prospective
- Sector
- Manufacturing (Industrial)
- Location
- United States of America
- Updated
- 19 Nov 2026
- Source
- Deutsche Investitions- und Entwicklungsgesellschaft (DEG)
ConstructChat
Ask ConstructChat about Kelix bio Ltd
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | active |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | KELIX bio Ltd. (“Kelix bio”) was created in 2020 by the PE investor Development Partners International LLP (DPI), EBRD and BII (former CDC) to become the consolidating group holding of the African build-and buy-platform. The platform’s strategy is to build a vertically integrated manufacturer and wholesaler of specialty generics and biosimilar drugs in fast growing segments like oncology, diabetes, autoimmune diseases, respiratory and critical care. The core of the company is an established Indian biopharma company with advanced Research and Development capacity. Acquired subsidiaries in the Egypt and Morocco enable access to the African local markets via established registration processes and distribution channels.Alongside DPI and other DFIs DEG will invest up to USD 20 mln to acquire an indirect stake in African buy-and-build platform Kelix bio Ltd. The funds raised in this equity round will be used to fund acquisitions of Moroccan pharma company and Egyptian pharmaceutical plant, additional capex and holding expenses.Developmental Impact of the transaction is expected to be high and driven by transferring the know-how for production of complex generic pharmaceutical products from India to Egypt and Morocco, and thereby en-hancing the availability and affordability of special generic drugs in African markets. The local production will contribute to growth of local income and decent jobs in MENA region. DEG equity investment supports the company’s growth in Egypt and facilitate the entrance in the Moroccan pharmaceutical market. Together with DPI, DEG will support Kelix bio Ltd. in establishing high-level ESG, reporting and corporate governance standards across the platform.Kelix bio is a good fit to DEG’s strategic goals as the pharmaceutical platform is in one of DEG’s focus sec-tors providing essential pharma goods to the African population in a defensive and crisis-resilient market and high development impact by enhancing availability (and manufacturing) and affordability of drugs in African markets. The engagement thus contributes to the Sustainable Development Goals, in particular SDG 3. |
Original sector | Industry |
Budget |
Location
Country | United States of America (USA) |
Source
Source | Deutsche Investitions- und Entwicklungsgesellschaft (DEG) |
URL |
More Details
Record type | Project |
Sector | Manufacturing (Industrial) |
Article published date | 2024-05-29 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
